News & Updates

Treatment with colchicine for 6 months when commencing urate-lowering therapy (ULT) provides no additional benefit in achieving gout remission regardless of the definition used, according to a study.

Use of anifrolumab improves symptoms and induces remission in patients with refractory systemic lupus erythematosus (SLE), with an acceptable safety profile, a study has shown.

Treatment of symptomatic COVID-19 with nirmatrelvir/ritonavir in children at least 6 years of age who are at risk of progression to severe disease appears to be safe and well-tolerated, with pharmacokinetic data from the open-label phase 2/3 EPIC-Peds* study indicating suitable dosing regimens for two distinct weight categories of this population.

The incidence of death is comparable between patients with acute myocardial infarction (MI) without heart failure (HF) receiving angiotensin II receptor blockers (ARBs) and those taking angiotensin-converting enzyme inhibitors (ACEIs), a study has shown.

Use of SGLT-2 inhibitors may reduce the risk of all-cause and cardiovascular (CV) mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), reports a study.

Treatment with trastuzumab deruxtecan (T-DXd) demonstrates efficacy in patients with metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer but may result in adverse events, such as interstitial lung disease (ILD), suggests a study.

Treatment with sacituzumab govitecan (SG), a novel antibody-drug conjugate, provides survival benefits in women diagnosed with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2–) breast cancer, reports a study.